VNRX
VolitionRx Limited (AMEX)
Healthcare — Medical Devices
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.
Price History
Fundamentals
| Market Cap | $16.21M |
| P/E Ratio (TTM) | - |
| Forward P/E | -1.18 |
| EPS (TTM) | $-4.25 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | 299.80% |
| ROE | - |
| Debt/Equity | - |
| Recommendation | Buy 1.6 |
| Analyst Target | $16.97 |
| Analysts | 5 |
| Indexes | AMEX |
Technical Indicators
| RSI (14) | 43.7 |
| Beta | 1.04 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $16.00 |
| 52-Week Low | $1.17 |
| 50-Day Avg | $2.13 |
| 200-Day Avg | $5.40 |
| Avg Volume | 284.4K |
| Volume | 4.2K |
Performance Analysis
BULLISHVNRX shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:37 UTC
Back to Screener Export Report